Morning Briefing
Summaries of health policy coverage from major news organizations
IPS Examines Access To Treatment For Drug-Resistant TB
"Access to treatment for drug-resistant tuberculosis (DR-TB) remains compromised, especially in developing countries, because too few pharmaceutical companies manufacture quality-assured drugs," Inter Press Service reports in an article examining how a lack of competition and a working mechanism to keep prices low "has led to skyrocketing prices."
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
